While decitabine is mainly used in adult oncology, its application in pediatric oncology is emerging, especially for conditions such as juvenile myelomonocytic leukemia (JMML) and other pediatric myelodysplastic syndromes. The use of decitabine in children often requires careful consideration of dosing, administration, and monitoring due to differences in metabolism and side effect profiles compared to adults.
